DK3219720T3 - Wdrpuh-epitoppeptider og vacciner, der indeholder disse - Google Patents

Wdrpuh-epitoppeptider og vacciner, der indeholder disse Download PDF

Info

Publication number
DK3219720T3
DK3219720T3 DK17167553.1T DK17167553T DK3219720T3 DK 3219720 T3 DK3219720 T3 DK 3219720T3 DK 17167553 T DK17167553 T DK 17167553T DK 3219720 T3 DK3219720 T3 DK 3219720T3
Authority
DK
Denmark
Prior art keywords
epitoppeptides
wdrpuh
vaccines containing
vaccines
wdrpuh epitoppeptides
Prior art date
Application number
DK17167553.1T
Other languages
English (en)
Inventor
Takuya Tsunoda
Ryuji Ohsawa
Sachiko Yoshimura
Tomohisa Watanabe
Original Assignee
Onco Therapy Science Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Onco Therapy Science Inc filed Critical Onco Therapy Science Inc
Application granted granted Critical
Publication of DK3219720T3 publication Critical patent/DK3219720T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/03—Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464402—Receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK17167553.1T 2008-12-05 2009-12-03 Wdrpuh-epitoppeptider og vacciner, der indeholder disse DK3219720T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US20096208P 2008-12-05 2008-12-05
US20970409P 2009-03-09 2009-03-09
EP09830200.3A EP2370454A4 (en) 2008-12-05 2009-12-03 PEPTIDES WITH EPITAOPE WDRPUH AND VACCINES INCLUDING THEM

Publications (1)

Publication Number Publication Date
DK3219720T3 true DK3219720T3 (da) 2022-05-09

Family

ID=42233088

Family Applications (1)

Application Number Title Priority Date Filing Date
DK17167553.1T DK3219720T3 (da) 2008-12-05 2009-12-03 Wdrpuh-epitoppeptider og vacciner, der indeholder disse

Country Status (18)

Country Link
US (3) US8541546B2 (da)
EP (3) EP4047009A3 (da)
JP (1) JP5764823B2 (da)
KR (1) KR101705102B1 (da)
CN (2) CN104650183B (da)
AU (1) AU2009323523B2 (da)
BR (1) BRPI0922844A2 (da)
CA (2) CA3031126C (da)
DK (1) DK3219720T3 (da)
ES (1) ES2913148T3 (da)
IL (2) IL212945B (da)
MX (1) MX2011005944A (da)
NZ (2) NZ605799A (da)
RU (1) RU2514386C2 (da)
SG (1) SG171977A1 (da)
TW (2) TWI500932B (da)
WO (1) WO2010064430A1 (da)
ZA (1) ZA201104890B (da)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013133405A1 (ja) 2012-03-09 2013-09-12 オンコセラピー・サイエンス株式会社 ペプチドを含む医薬組成物
DK2895600T3 (da) 2012-09-11 2020-04-27 Onco Therapy Science Inc Ube2t-peptider og vacciner, der indeholder disse

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4722848A (en) 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5804566A (en) 1993-08-26 1998-09-08 The Regents Of The University Of California Methods and devices for immunizing a host through administration of naked polynucleotides with encode allergenic peptides
US5679647A (en) 1993-08-26 1997-10-21 The Regents Of The University Of California Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides
US5739118A (en) 1994-04-01 1998-04-14 Apollon, Inc. Compositions and methods for delivery of genetic material
US5736524A (en) 1994-11-14 1998-04-07 Merck & Co.,. Inc. Polynucleotide tuberculosis vaccine
US5922687A (en) 1995-05-04 1999-07-13 Board Of Trustees Of The Leland Stanford Junior University Intracellular delivery of nucleic acids using pressure
WO1997005900A1 (en) 1995-08-03 1997-02-20 Rijksuniversiteit Te Leiden Cell derived antigen presenting vesicles
US5853719A (en) 1996-04-30 1998-12-29 Duke University Methods for treating cancers and pathogen infections using antigen-presenting cells loaded with RNA
WO1998004720A1 (en) 1996-07-26 1998-02-05 Sloan-Kettering Institute For Cancer Research Method and reagents for genetic immunization
FR2766205B1 (fr) 1997-07-16 2002-08-30 Inst Nat Sante Rech Med Nouveau procede de sensibilisation de cellules presentatrices d'antigene et nouveaux moyens pour la mise en oeuvre du procede
US7041297B1 (en) 1998-06-25 2006-05-09 Sumitomo Pharmaceuticals Company Tumor antigen peptides originating in cyclophilin B
CA2488404C (en) 2002-06-06 2012-11-27 Oncotherapy Science, Inc. Genes and polypeptides relating to human colon cancers
CN101613405A (zh) * 2002-06-06 2009-12-30 肿瘤疗法科学股份有限公司 与人结肠癌相关的基因和多肽
EP2267021B1 (en) * 2002-09-12 2015-02-18 Oncotherapy Science, Inc. KDR peptides and vaccines comprising the same
CA2580412A1 (en) 2004-09-13 2006-03-23 Government Of The United States Of America, Represented By The Secretary , Department Of Health And Human Services Compositions comprising t cell receptors and methods of use thereof
ES2364670T3 (es) 2005-02-25 2011-09-12 Oncotherapy Science, Inc. Vacunas de péptidos para cánceres de pulmón que expresan polipéptidos ttk.
KR101130597B1 (ko) 2005-09-13 2012-04-02 다카라 바이오 가부시키가이샤 Ｔ 세포 리셉터 및 그 리셉터를 코드하는 핵산
TWI610939B (zh) 2007-02-21 2018-01-11 腫瘤療法 科學股份有限公司 表現腫瘤相關抗原之癌症的胜肽疫苗
TW201425333A (zh) * 2007-04-11 2014-07-01 Oncotherapy Science Inc 腫瘤血管內皮標誌８胜肽及包含此胜肽之疫苗
TW201008574A (en) 2008-08-19 2010-03-01 Oncotherapy Science Inc INHBB epitope peptides and vaccines containing the same

Also Published As

Publication number Publication date
AU2009323523A1 (en) 2010-06-10
KR101705102B1 (ko) 2017-02-22
ZA201104890B (en) 2012-03-28
RU2514386C2 (ru) 2014-04-27
TWI539160B (zh) 2016-06-21
CA3031126A1 (en) 2010-06-10
KR20110099018A (ko) 2011-09-05
CN102307891A (zh) 2012-01-04
BRPI0922844A2 (pt) 2015-12-29
NZ605799A (en) 2014-03-28
CA2745408A1 (en) 2010-06-10
CN102307891B (zh) 2015-02-04
EP2370454A4 (en) 2013-11-20
US9745343B2 (en) 2017-08-29
EP4047009A3 (en) 2022-11-16
TWI500932B (zh) 2015-09-21
US20130315942A1 (en) 2013-11-28
IL212945A0 (en) 2011-07-31
JP2012510794A (ja) 2012-05-17
EP3219720A3 (en) 2018-01-03
EP2370454A1 (en) 2011-10-05
CA2745408C (en) 2019-03-12
NZ593086A (en) 2013-02-22
US20150315239A1 (en) 2015-11-05
US20110293645A1 (en) 2011-12-01
AU2009323523B2 (en) 2016-08-11
RU2011127429A (ru) 2013-01-10
MX2011005944A (es) 2011-07-28
ES2913148T3 (es) 2022-05-31
CN104650183B (zh) 2018-04-20
IL212945B (en) 2018-03-29
CA3031126C (en) 2022-03-22
SG171977A1 (en) 2011-07-28
EP3219720A2 (en) 2017-09-20
TW201027074A (en) 2010-07-16
TW201510529A (zh) 2015-03-16
US8541546B2 (en) 2013-09-24
JP5764823B2 (ja) 2015-08-19
IL228266A (en) 2016-09-29
EP4047009A2 (en) 2022-08-24
US9115207B2 (en) 2015-08-25
CN104650183A (zh) 2015-05-27
EP3219720B1 (en) 2022-03-09
WO2010064430A1 (en) 2010-06-10

Similar Documents

Publication Publication Date Title
DK2147315T3 (da) Diabetesrelaterede biomarkører og fremgangsmåder til anvendelse deraf
BRPI0909770A2 (pt) Vacina, e, kit
DK2337568T3 (da) Fremgangsmåder og midler til blødvævsteknologi
DK2467173T3 (da) Sårbandager, fremgangsmåder til anvendelse heraf og fremgangsmåder til dannelse deraf
BRPI0913227A2 (pt) método, e objeto
DK3338790T3 (da) Oligopeptid-forbindelser og anvendelser deraf
DK2376791T3 (da) Afstandsindretning og fastgørelsesindretning med afstandsindretning
BRPI0907231A2 (pt) pirrolpirimidinas e pirrolpiridinas
BRPI0912799A2 (pt) fluxímetro, e, método
DK2118140T3 (da) Humancytomegalovirus-neutraliserende antistoffer og anvendelse deraf
DK2120591T3 (da) Ny drikkeyoghurt og fremgangsmåde til fremstilling deraf
DK2270818T3 (da) Polyelektrolyt og fremgangsmåde til fremstilling af polyelektrolytten
DK2320911T3 (da) Vasokonstriktionspræparater og fremgangsmåder til anvendelse deraf
DK2452880T3 (da) Poseforsegler og isautomat, der anvender samme
DK2170827T3 (da) Indolin-2-oner og aza-indolin-2-oner
BRPI0913752A2 (pt) método, dispositivo, e, estrutura
BRPI0919575A2 (pt) método, e, composição
BRPI0915433A2 (pt) método, e, dispositivo.
DK2252633T3 (da) Anti-TrkA antistoffer og derivater deraf
BRPI0809573A8 (pt) composição, e, método
CR10571A (es) Vacuna virica recombinante
DK2245032T3 (da) Folater, sammensætninger og anvendelser deraf
BRPI0913112A2 (pt) fluxímetro, e, método.
DK2328931T3 (da) Selektive anti-hepcidin-25-antistoffer og anvendelser deraf
DK2337837T3 (da) Alpha-amylase-blandinger og fremgangsmåder til anvendelse heraf